Hereditary Endocrine Tumor Registries
Open Access
- 23 December 2022
- journal article
- research article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (3), bvac194
- https://doi.org/10.1210/jendso/bvac194
Abstract
Introduction and hypothesis Endocrine neoplasia syndromes are phenotypically complex and there is a misconception that they are universally rare. Genetic alterations are increasingly recognized, however true prevalence is unknown. The purpose of a clinical registry is to monitor the quality of health care delivered to a specified group of patients through the collection, analysis and reporting of relevant health-related information. This leads to improved clinical practice, decision making, patient satisfaction and outcome. This review aims to identify, compare and contrasts active registries worldwide that capture data relevant to HET (hereditary endocrine tumours). Methods Clinical registries were identified using a systematic approach from publications (Ovid MEDLINE, EMBASE) peer consultation, clinical trials and web searches. Inclusion criteria were hereditary endocrine tumours, clinical registries and English language. Exclusion criteria were institutional audits, absence of clinical data or inactive. Details surrounding general characteristics, funding, data fields, collection periods and entry methods were collated. Results Fifteen registries specific for HET were shortlisted with 136 affiliated peer reviewed manuscripts. Conclusions There are few clinical registries specific to HET. Most of these are European and the data collected is highly variable. Further research into their effectiveness is warranted. We note the absence of an Australian registry for all HET, where potential health and economic gains may be possible. This review presents a unique opportunity to harmonize registry data for HET locally and further afield.This publication has 149 references indexed in Scilit:
- Integrative analysis of SF-1 transcription factor dosage impact on genome-wide binding and gene expression regulationNucleic Acids Research, 2013
- Genotype-Specific Abnormalities in Mitochondrial Function Associate with Distinct Profiles of Energy Metabolism and Catecholamine Content in Pheochromocytoma and ParagangliomaClinical Cancer Research, 2013
- Silencing Mutated β-Catenin Inhibits Cell Proliferation and Stimulates Apoptosis in the Adrenocortical Cancer Cell Line H295RPLOS ONE, 2013
- Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor modelsEndocrine-Related Cancer, 2012
- MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and ParagangliomaClinical Cancer Research, 2012
- Staging and Functional Characterization of Pheochromocytoma and Paraganglioma by 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission TomographyJNCI Journal of the National Cancer Institute, 2012
- Animal models of adrenocortical tumorigenesisMolecular and Cellular Endocrinology, 2012
- Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal TumorsJournal of Clinical Endocrinology & Metabolism, 2011
- Adrenocortical neoplasia: evolving concepts in tumorigenesis with an emphasis on adrenal cortical carcinoma variantsVirchows Archiv, 2011
- Regulation of Insulin-like Growth Factor–Mammalian Target of Rapamycin Signaling by MicroRNA in Childhood Adrenocortical TumorsCancer Research, 2010